Durvalumab (Imfinzi) combined with tremelimumab (Imjudo) produced high survival and deep response signals in cohort 2 of the INFINITY phase 2 trial in resectable microsatellite instability-high gastric and gastroesophageal junction cancer. Results were presented during AACR Annual Meeting 2026 programming. Among 18 enrolled patients, three grade 3 immune-related adverse events occurred with no grade 4/5 events and no treatment discontinuations. With 17 evaluable for efficacy two years later, 100% were alive, the clinical complete response rate was 71%, and progression-free survival reached 94.1%, alongside a 70.6% gastrectomy-free survival rate. Exploratory ctDNA analysis showed baseline positivity in 13 of 17 evaluable patients and clearance in 11 of those 13 after treatment, supporting the potential for molecular response tracking alongside imaging and pathology endpoints.